OasisLMS

Description
With the increasing adoption of stereoelectroencephalography (SEEG) for presurgical evaluation in drug-resistant epilepsy, clinicians face challenges in consistently formulating robust preimplantation hypotheses and accurately interpreting SEEG signals. These skills are critical for precise localization of the epileptogenic zone, yet variability in practice may limit surgical success. This session will address these gaps by reviewing best practices in hypothesis generation, highlighting key principles of anatomo-electro-clinical correlation, and providing practical strategies for systematic SEEG interpretation to optimize patient outcomes

At the end of this webinar, attendees should be able to:

1. Learn how to analyze seizure semiology and build SEEG hypothesis
    
2. Evaluate interictal and ictal SEEG data to localize the epileptogenic zone
    
3. Combine pre-SEEG and SEEG findings to make informed surgical decisions
    

Fabrice Bartolomei, MD, PhD
Pr. Fabrice Bartolomei is a renowned neurologist and professor of clinical neurophysiology at the Aix Marseille University. He is the head of the Epileptology Department and Clinical Neurophysiology Unit at La Timone University Hospital in Marseille, France. He is co-leading the DYNAMAP team of the “Institut de Neurosciences des Systèmes” INSERM U1106 research unit. Pr. Bartolomei is internationally recognized for his expertise in epilepsy, specifically in stereoelectroencephalography (SEEG) and the surgical treatment of drug-resistant epilepsy. His pioneering work has significantly advanced the understanding of epilepsy networks and the mechanisms underlying seizure generation and propagation.


Jaysingh Singh, MD

Jaysingh Singh, M.D., is an Associate Professor of Neurology at The Ohio State University Wexner Medical Center, where he serves as the Medical Director of the Epilepsy Surgery Program. He co-chairs the American Stereo-EEG Consortium and is vice chair of the American Epilepsy Society’s Online Education Committee. Dr. Singh also serves on the Editorial Board of the Journal of Clinical Neurophysiology. A recognized expert in Stereo-EEG, he is a frequently invited speaker at AES, ACNS, and international SEEG courses. His research focuses on pre-surgical evaluation, stereo-EEG signal analysis, and EEG source imaging.

Disclosure Policy
It is the policy of the American Epilepsy Society (AES) to ensure balance, independence, objectivity and scientific rigor. All individuals involved in the selection, development and presentation of content are required to disclose any real or apparent conflicts of interest. Conflicts of interest will be resolved by AES prior to an educational activity being delivered to learners.

Planning Committee, Faculty, Reviewers' Disclosures of Financial Relationships
In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, the AES requires that any person who is in a position to control content of a CME activity must disclose all relevant financial relationships that they have with an ineligible company. Unless otherwise indicated (*), none of the planners or faculty of this activity have any financial relationships to disclose. All relevant financial relationships with ineligible companies have been mitigated. The following individuals contributed to this activity's content. Update for all courses this year.

American Epilepsy Society Staff Planners
Melissa Ball, CAE, PMP

Resolution of Conflicts of Interest
It is the policy of the American Epilepsy Society to ensure balance, independence, objectivity and scientific rigor. All persons involved in the selection, development and presentation of content are required to disclose any real or apparent conflicts of interest. In accordance with the ACCME Standards for Commercial Support of CME, the AES implemented the mechanisms of prospective peer review of this CME activity, to identify and resolve any conflicts. Additionally, the content of this activity is based on the best available evidence.

Accreditation
The American Epilepsy Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

For more information regarding contact hours, please call American Epilepsy Society 312.883.3800 or education@aesnet.org.

Credit Designation
The American Epilepsy Society designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME Certificate
To receive credit for your participation in this activity, please complete the evaluation survey provided at the conclusion of the activity.

Unapproved Use Disclosure
The American Epilepsy Society requires CME authors to disclose to learners when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information. Information about pharmaceutical agents/devices that is outside of U.S. Food and Drug Administration approved labeling may be contained in this activity.

Disclaimer
This CME activity is for educational purposes only and does not constitute the opinion or endorsement of, or promotion by, the American Epilepsy Society. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label, investigational and/or experimental uses.